여행용 백신 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Travel Vaccines Market size is expected to reach USD 13.85 Billion in 2034 from USD 5.81 Billion (2025) growing at a CAGR of 10.12% during 2026-2034.

The travel vaccines market is growing steadily as international mobility, tourism, and global workforce expansion increase. Travel vaccines protect against infectious diseases prevalent in different regions, making them essential for safeguarding public health. With rising awareness and expanding vaccination campaigns, more travelers are prioritizing immunization as a preventive measure before international journeys.

Innovation in biotechnology is reshaping the landscape. Advances in recombinant technology, adjuvants, and needle-free delivery systems are improving efficacy, safety, and patient compliance. Combination vaccines that protect against multiple pathogens are simplifying immunization schedules, particularly for frequent travelers and healthcare workers. Digital platforms are further enhancing vaccine accessibility through scheduling, education, and personalized health recommendations.

Future growth will be driven by global health security initiatives and pandemic preparedness. Governments, NGOs, and private companies are investing in vaccine research, production, and distribution infrastructure. The rise of adventure tourism, corporate travel, and cross-border migration is expected to sustain strong demand. As biotechnology and digital health converge, the travel vaccines market is poised to play an integral role in ensuring global mobility and resilience against infectious diseases.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Composition

• Mono Vaccines
• Combination Vaccines

By Disease Type

• Hepatitis A
• Hepatitis B
• Influenza
• Diphtheria Pertussis Tetanus (DPT)
• Rabies
• Yellow Fever
• Typhoid
• Measles And Mumps
• Meningococcal
• Other Disease Vaccines

By Application

• Outbound Travel
• Domestic Travel

COMPANIES PROFILED

• GSK plc, Sanofi, Janssen Pharmaceuticals Inc, Pfizer Inc, CSL Ltd, Qiagen NV, AstraZeneca, F HoffmannLa Roche Ltd, Abbott Laboratories, Valneva Inc
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL TRAVEL VACCINES MARKET: BY COMPOSITION 2022-2034 (USD MN and Million Doses)

• 4.1. Market Analysis, Insights and Forecast Composition
• 4.2. Mono Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 4.3. Combination Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 5. GLOBAL TRAVEL VACCINES MARKET: BY DISEASE TYPE 2022-2034 (USD MN and Million Doses)

• 5.1. Market Analysis, Insights and Forecast Disease Type
• 5.2. Hepatitis A Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.3. Hepatitis B Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.4. Influenza Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.5. Diphtheria Pertussis Tetanus (DPT) Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.6. Rabies Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.7. Yellow Fever Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.8. Typhoid Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.9. Measles And Mumps Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.10. Meningococcal Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 5.11. Other Disease Vaccines Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 6. GLOBAL TRAVEL VACCINES MARKET: BY APPLICATION 2022-2034 (USD MN and Million Doses)

• 6.1. Market Analysis, Insights and Forecast Application
• 6.2. Outbound Travel Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)
• 6.3. Domestic Travel Estimates and Forecasts By Regions 2022-2034 (USD MN and Million Doses)

Chapter 7. GLOBAL TRAVEL VACCINES MARKET: BY REGION 2022-2034(USD MN and Million Doses)

• 7.1. Regional Outlook
• 7.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.2.1 By Composition
  • 7.2.2 By Disease Type
  • 7.2.3 By Application
  • 7.2.4 United States
  • 7.2.5 Canada
  • 7.2.6 Mexico
• 7.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.3.1 By Composition
  • 7.3.2 By Disease Type
  • 7.3.3 By Application
  • 7.3.4 United Kingdom
  • 7.3.5 France
  • 7.3.6 Germany
  • 7.3.7 Italy
  • 7.3.8 Russia
  • 7.3.9 Rest Of Europe
• 7.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.4.1 By Composition
  • 7.4.2 By Disease Type
  • 7.4.3 By Application
  • 7.4.4 India
  • 7.4.5 Japan
  • 7.4.6 South Korea
  • 7.4.7 Australia
  • 7.4.8 South East Asia
  • 7.4.9 Rest Of Asia Pacific
• 7.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.5.1 By Composition
  • 7.5.2 By Disease Type
  • 7.5.3 By Application
  • 7.5.4 Brazil
  • 7.5.5 Argentina
  • 7.5.6 Peru
  • 7.5.7 Chile
  • 7.5.8 South East Asia
  • 7.5.9 Rest of Latin America
• 7.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN and Million Doses)
  • 7.6.1 By Composition
  • 7.6.2 By Disease Type
  • 7.6.3 By Application
  • 7.6.4 Saudi Arabia
  • 7.6.5 UAE
  • 7.6.6 Israel
  • 7.6.7 South Africa
  • 7.6.8 Rest of the Middle East And Africa

Chapter 8. COMPETITIVE LANDSCAPE

• 8.1. Recent Developments
• 8.2. Company Categorization
• 8.3. Supply Chain & Channel Partners (based on availability)
• 8.4. Market Share & Positioning Analysis (based on availability)
• 8.5. Vendor Landscape (based on availability)
• 8.6. Strategy Mapping

Chapter 9. COMPANY PROFILES OF GLOBAL TRAVEL VACCINES INDUSTRY

• 9.1. Top Companies Market Share Analysis
• 9.2. Company Profiles
  • 9.2.1 GSK Plc
  • 9.2.2 Sanofi
  • 9.2.3 Janssen Pharmaceuticals Inc
  • 9.2.4 Pfizer Inc
  • 9.2.5 CSL Ltd
  • 9.2.6 Qiagen N.V
  • 9.2.7 AstraZeneca
  • 9.2.8 F. Hoffmann-La Roche Ltd
  • 9.2.9 Abbott Laboratories
  • 9.2.10 Valneva Inc